US6861511B1
(en)
*
|
1986-06-04 |
2005-03-01 |
Bayer Corporation |
Detection and quantification of neu related proteins in the biological fluids of humans
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
EP0444181B2
(de)
*
|
1989-08-04 |
2010-11-24 |
Bayer Schering Pharma Aktiengesellschaft |
Äusserliche domäne von c-erbb-2:gp75
|
US7282345B1
(en)
|
1989-08-04 |
2007-10-16 |
Schering Ag |
C-erbB-2 external domain: GP75
|
DK0617124T3
(da)
*
|
1990-01-26 |
1999-12-06 |
Washington Res Found |
Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster
|
EP0444961A1
(de)
*
|
1990-03-02 |
1991-09-04 |
Bristol-Myers Squibb Company |
Her3: Ein neues EGF-Rezeptor Homologes
|
US5578482A
(en)
*
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
AU662311B2
(en)
*
|
1991-02-05 |
1995-08-31 |
Novartis Ag |
Recombinant antibodies specific for a growth factor receptor
|
US7094749B1
(en)
|
1991-04-10 |
2006-08-22 |
Acorda Therapeutics, Inc. |
Glial mitogenic factors, their preparation and use
|
US7115554B1
(en)
|
1993-05-06 |
2006-10-03 |
Acorda Therapeutics, Inc. |
Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
|
US7135456B1
(en)
|
1991-04-10 |
2006-11-14 |
Acorda Therapeutics, Inc. |
Glial mitogenic factors, their preparation and use
|
US7319019B1
(en)
|
1991-04-10 |
2008-01-15 |
Acorda Therapeutics, Inc. |
Glial mitogenic factors lacking an N-terminal signal sequence
|
US7285531B1
(en)
|
1991-04-10 |
2007-10-23 |
Acorda Therapeutics, Inc. |
Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
|
US5530109A
(en)
*
|
1991-04-10 |
1996-06-25 |
Ludwig Institute For Cancer Research |
DNA encoding glial mitogenic factors
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
DE4129533A1
(de)
*
|
1991-09-05 |
1993-03-11 |
Max Planck Gesellschaft |
Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
|
DE69219787T2
(de)
*
|
1991-11-29 |
1997-08-28 |
Viagene Inc |
Immuntherapeutische vektorkonstrukte gegen krebs
|
US7037888B1
(en)
|
1992-04-03 |
2006-05-02 |
Acorda Therapeutics, Inc. |
Methods for treating muscle diseases and disorders
|
GB9217316D0
(en)
*
|
1992-08-14 |
1992-09-30 |
Ludwig Inst Cancer Res |
Schwann cell mitogenic factor,its preparation and use
|
CA2103323A1
(en)
*
|
1992-11-24 |
1994-05-25 |
Gregory D. Plowman |
Her4 human receptor tyrosine kinase
|
US5801005A
(en)
*
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
US6953573B1
(en)
|
1993-03-17 |
2005-10-11 |
University Of Washington |
Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
|
US5869445A
(en)
*
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
US7794729B2
(en)
|
1994-11-08 |
2010-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for immunotherapy of cancer
|
US8114414B2
(en)
*
|
1994-11-08 |
2012-02-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical cancer
|
US7820180B2
(en)
*
|
2004-09-24 |
2010-10-26 |
The Trustees Of The University Of Pennsylvania |
Listeria-based and LLO-based vaccines
|
US20070264279A1
(en)
*
|
1994-11-08 |
2007-11-15 |
Claudia Gravekamp |
Compositions and methods comprising a MAGE-b antigen
|
US8956621B2
(en)
|
1994-11-08 |
2015-02-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical dysplasia
|
US8791237B2
(en)
*
|
1994-11-08 |
2014-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of non-hodgkins lymphoma
|
US6514942B1
(en)
*
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
IT1276662B1
(it)
*
|
1995-04-04 |
1997-11-03 |
Uni Degli Studi Camerino |
Vaccini polinucleotidici
|
US6465623B2
(en)
|
1995-05-02 |
2002-10-15 |
Garvan Institute Of Medical Research |
GDU, a novel signalling protein
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
JP4033497B2
(ja)
|
1996-09-06 |
2008-01-16 |
三菱化学株式会社 |
ワクチン製剤
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
US20040202680A1
(en)
*
|
1997-01-30 |
2004-10-14 |
O'hagan Derek |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
ATE235890T1
(de)
*
|
1997-01-30 |
2003-04-15 |
Chiron Corp |
Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20010023241A1
(en)
*
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
US6541214B1
(en)
*
|
1998-11-13 |
2003-04-01 |
Oregon Heath Science University |
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7198920B1
(en)
*
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
CA2361009C
(en)
*
|
1999-01-29 |
2012-10-23 |
Corixa Corporation |
Her-2/neu fusion proteins
|
US7049410B2
(en)
*
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
AU5003200A
(en)
|
1999-05-14 |
2000-12-05 |
United States Of America As Represented By The Department Of Veterans Affairs, The |
Isolation and characterization of epidermal growth factor related protein
|
EP1189641B1
(de)
|
1999-06-25 |
2009-07-29 |
Genentech, Inc. |
Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
JP4579471B2
(ja)
*
|
1999-06-25 |
2010-11-10 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる前立腺癌の処置
|
US7060284B1
(en)
|
1999-08-03 |
2006-06-13 |
The Ohio State University |
Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
|
AU7743100A
(en)
*
|
1999-09-30 |
2001-04-30 |
Corixa Corporation |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
US7378096B2
(en)
|
1999-09-30 |
2008-05-27 |
Health Research, Inc. |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
US20020039583A1
(en)
*
|
1999-09-30 |
2002-04-04 |
Subjeck John R. |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
KR20020073181A
(ko)
|
2000-01-25 |
2002-09-19 |
제넨테크, 인크. |
Liv-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
|
AU2001241710B2
(en)
*
|
2000-02-25 |
2005-07-21 |
The Regents Of The University Of California |
Membrane estrogen receptor-directed therapy in breast cancer
|
US9012141B2
(en)
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
EP1303299B1
(de)
*
|
2000-03-29 |
2010-07-28 |
The Trustees of The University of Pennsylvania |
Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
|
ES2528794T3
(es)
|
2000-04-11 |
2015-02-12 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
CN102698265A
(zh)
|
2000-05-19 |
2012-10-03 |
杰南技术公司 |
用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
EP1236740B1
(de)
*
|
2001-02-28 |
2012-07-18 |
Bio Life Science Forschungs- und Entwicklungsges.m.b.H. |
Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
|
US8771702B2
(en)
|
2001-03-26 |
2014-07-08 |
The Trustees Of The University Of Pennsylvania |
Non-hemolytic LLO fusion proteins and methods of utilizing same
|
US7700344B2
(en)
*
|
2001-03-26 |
2010-04-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing the immunogenicity of antigens
|
JP4398644B2
(ja)
*
|
2001-04-06 |
2010-01-13 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア |
ErbB界面ペプチド擬態およびその使用方法
|
EP2305299B1
(de)
|
2001-05-31 |
2017-03-01 |
GlaxoSmithKline Biologicals SA |
Chimäre alphavirus-replikonpartikel
|
US7074175B2
(en)
|
2001-07-25 |
2006-07-11 |
Erik Schroeder Handy |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
US7951061B2
(en)
*
|
2001-07-25 |
2011-05-31 |
Allan Foreman |
Devices for targeted delivery of thermotherapy, and methods related thereto
|
US7731648B2
(en)
*
|
2001-07-25 |
2010-06-08 |
Aduro Biotech |
Magnetic nanoscale particle compositions, and therapeutic methods related thereto
|
US6997863B2
(en)
*
|
2001-07-25 |
2006-02-14 |
Triton Biosystems, Inc. |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
AU2002365258A1
(en)
*
|
2001-10-12 |
2003-09-02 |
University Of Vermont And State Agricultural College |
Binding peptides specific for the extracellular domain of erbb2 and uses therefor
|
JP4405916B2
(ja)
|
2002-05-23 |
2010-01-27 |
トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Fasペプチド模倣体およびその使用
|
WO2004048525A2
(en)
*
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
US20040156846A1
(en)
*
|
2003-02-06 |
2004-08-12 |
Triton Biosystems, Inc. |
Therapy via targeted delivery of nanoscale particles using L6 antibodies
|
PT2248899E
(pt)
|
2003-03-19 |
2015-09-23 |
Biogen Ma Inc |
Proteína de ligação do receptor nogo
|
WO2005016966A2
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
EP1745073A2
(de)
*
|
2004-05-14 |
2007-01-24 |
Receptor Biologix, Inc. |
Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
|
CA2568952C
(en)
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP1768662A2
(de)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immunstimulatoren kleiner moleküle und assays für deren nachweis
|
CA2571421A1
(en)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Compounds for immunopotentiation
|
ES2395094T3
(es)
|
2004-06-24 |
2013-02-08 |
Biogen Idec Ma Inc. |
Tratamiento de afecciones que implican la desmielinización
|
US20080206231A1
(en)
*
|
2004-10-05 |
2008-08-28 |
Oregon Health And Science University |
Compositions and Methods for Treating Disease
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP3698807A1
(de)
|
2005-01-21 |
2020-08-26 |
Genentech, Inc. |
Fixe dosierung von her-antikörpern
|
CA2595395A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Genentech, Inc. |
Inhibiting her2 shedding with matrix metalloprotease antagonists
|
AU2006216732C1
(en)
*
|
2005-02-23 |
2017-07-20 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US7691396B2
(en)
*
|
2005-06-15 |
2010-04-06 |
The Ohio State University Research Foundation |
Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes
|
MX2008000253A
(es)
|
2005-07-08 |
2008-04-02 |
Biogen Idec Inc |
Anticuerpos de sp35 y usos de los mismos.
|
PE20070207A1
(es)
*
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
JP5312039B2
(ja)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄の関与する状態の処置
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
CA2646539A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
WO2007109810A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
US8268326B2
(en)
*
|
2006-08-15 |
2012-09-18 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
ES2657168T3
(es)
*
|
2006-08-15 |
2018-03-01 |
The Trustees Of The University Of Pennsylvania |
Composiciones que comprenden HMW-MAA y fragmentos de este para el tratamiento del cáncer
|
EP2084267B1
(de)
*
|
2006-09-26 |
2018-04-11 |
Cedars-Sinai Medical Center |
Krebsstammzellen-antigen-impfstoffe und entsprechende verfahren
|
CA2700436C
(en)
|
2006-09-28 |
2017-04-18 |
John S. Yu |
Cancer vaccines and vaccination methods
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
US8222214B2
(en)
|
2007-06-01 |
2012-07-17 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Vaccine for the prevention of breast cancer relapse
|
WO2008154249A2
(en)
*
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
WO2009143167A2
(en)
|
2008-05-19 |
2009-11-26 |
Advaxis |
Dual delivery system for heterologous antigens
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
ES2565779T3
(es)
*
|
2008-09-02 |
2016-04-06 |
Cedars-Sinai Medical Center |
Epítopos CD133
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
ES2637068T3
(es)
|
2009-03-04 |
2017-10-10 |
The Trustees Of The University Of Pennsylvania |
Composiciones que comprenden factores angiogénicos y métodos de uso de las mismas
|
ES2572728T3
(es)
|
2009-03-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HER biespecíficos
|
JP5705836B2
(ja)
|
2009-05-29 |
2015-04-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
US8895017B2
(en)
|
2010-06-07 |
2014-11-25 |
Pfizer Inc. |
HER-2 peptides and vaccines
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CN103687611A
(zh)
|
2011-03-11 |
2014-03-26 |
阿德瓦希斯公司 |
基于李斯特菌属的佐剂
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
CN108434440B
(zh)
|
2011-09-06 |
2022-08-23 |
新加坡科技研究局 |
多肽疫苗
|
DK2766040T3
(da)
|
2011-10-14 |
2019-07-22 |
Hoffmann La Roche |
Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
SG10201700392UA
(en)
|
2012-03-12 |
2017-03-30 |
Advaxis Inc |
Suppressor cell function inhibition following listeria vaccine treatment
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
WO2013173364A2
(en)
|
2012-05-14 |
2013-11-21 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
CA2898474A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
EP2777711A1
(de)
*
|
2013-03-11 |
2014-09-17 |
Icon Genetics GmbH |
HER2/neu-Krebsimpfstoff
|
AR095863A1
(es)
|
2013-04-16 |
2015-11-18 |
Genentech Inc |
Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
|
EP3502134B1
(de)
|
2014-03-11 |
2020-12-16 |
Molecular Templates, Inc. |
Proteine mit bindungsregionen, shiga-toxin und effektorregionen einer untereinheit und carboxyterminale, endoplasmatische retikulum-lokalisierungssignalmotive
|
JP6856378B2
(ja)
|
2014-03-11 |
2021-04-07 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
アミノ末端の近位にある志賀毒素aサブユニットエフェクター領域及び細胞標的化免疫グロブリン型結合領域を含むタンパク質
|
EP3134440A1
(de)
|
2014-04-25 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung von frühzeitigem brustkrebs mit trastuzumab-mcc-dm1 und pertuzumab
|
MX2017009038A
(es)
|
2015-01-08 |
2017-10-25 |
Biogen Ma Inc |
Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
|
CN107849096B
(zh)
|
2015-05-30 |
2022-05-24 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
EP3302551A2
(de)
|
2015-05-30 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Verfahren zur behandlung von her2-positivem, lokal fortgeschrittenem oder vorher unbehandeltem metastatischem brustkrebs
|
EP3325510A2
(de)
|
2015-07-26 |
2018-05-30 |
Molecular Templates, Inc. |
Gegen zellen gerichtete moleküle mit effektoren der shigatoxin-a-untereinheit und cd8+-t-zellepitopen
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
EP3454863A1
(de)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationstherapien zur behandlung von krebs
|
JP2019532999A
(ja)
|
2016-11-04 |
2019-11-14 |
ジェネンテック, インコーポレイテッド |
Her2陽性乳がんの治療
|
CN110099926A
(zh)
|
2016-12-28 |
2019-08-06 |
豪夫迈·罗氏有限公司 |
晚期her2表达性癌症的治疗
|
RU2750821C2
(ru)
|
2017-01-17 |
2021-07-05 |
Дженентек, Инк. |
Препараты антител против her2 для подкожного введения
|
WO2018140427A1
(en)
|
2017-01-25 |
2018-08-02 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
FI3589661T3
(fi)
|
2017-03-02 |
2024-01-31 |
Genentech Inc |
Her2-positiivisen rintasyövän adjuvanttihoito
|
CN110536969A
(zh)
|
2017-04-24 |
2019-12-03 |
豪夫迈·罗氏有限公司 |
跨膜或近膜域中的erbb2/her2突变
|
JP7323200B2
(ja)
|
2018-04-17 |
2023-08-08 |
モレキュラー テンプレーツ,インク. |
脱免疫化志賀毒素aサブユニット足場を含むher2ターゲティング分子
|